SuperworthFilana Therapeutics FLNA
- Market cap
- $30.7M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| R&D | $23.6M+27% | $18.7M+6% | $16.2M−27% | $15.2M−39% | $17.7M−25% | $20.5M+10% | $13.7M−16% | $5.1M−66% | $4M−78% | $3.9M−81% | $4.5M−67% | $3.3M−35% |
| SG&A | $4.3M+52% | $4.1M+24% | $3.7M−16% | $46.2M+1113% | $12.9M+203% | $9M+121% | $10.9M+195% | $40.3M−13% | $7.9M−39% | $9.7M+8% | $6.6M−39% | $6.1M−85% |
| −$27.9M+31% | −$22.8M+9% | −$19.9M−25% | −$61.4M+113% | −$30.6M+10% | −$29.5M+29% | −$24.6M+23% | −$45.4M−26% | −$11.9M−61% | −$13.6M−54% | −$11.2M−55% | −$9.4M−79% | |
| Pre-tax income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Net income | −$25.7M+27% | −$20.9M+9% | $25M | $6.2M | −$27.9M+9% | −$27.6M+32% | −$23.4M | −$44.2M | −$10.8M−61% | −$12.5M−55% | −$10.3M−56% | −$8.6M−81% |
| −$0.61 | −$0.50 | −$0.43−26% | $0.13 | −$0.58−5% | −$0.57+14% | −$0.48+12% | −$0.92 | −$0.22−62% | −$0.26−54% | n/a | n/a | |
| 42M | 42.2M | 44.1M+6% | 46.2M+11% | 48M+14% | 48.1M+14% | 48.3M+9% | 48.3M+5% | 48.3M+1% | 48.3M+0% | n/a | n/a |
EPS, diluted: 14 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 14 periods, Q4 FY10 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY13: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Filana Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| FLNAFilana Therapeutics | $30.7M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| Peer median | $69M | 11.1× | 14.5× | 0.4× | −3% | 3.7% |
More on Filana Therapeutics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .